New Dyneema Purity® TG grade enables smaller implants for next-generation surgical techniques28-Mar-08

– At the World Biomaterials Congress, May 28 till June 1, DSM will launch a new grade of its high-performance Dyneema Purity® polyethylene fiber portfolio that offers the same high specific strength as existing grades at significantly thinner diameters. This new product was developed specifically to help medical device manufacturers design smaller, lower-profile implants for minimally invasive surgical procedures without sacrificing strength and durability. Expansion of the Dyneema Purity® product portfolio is just one example of DSM’s strong commitment to the biomedical market. Through materials innovation and ongoing collaboration with medical device companies, DSM is firmly focused on enabling medical device companies to develop new clinical approaches that improve patient outcomes, including shorter recuperation times and less scarring.

The new product, Dyneema Purity® TG dtex 25 TS180 grade, offers a number of advantages over traditional materials. The new DSM product has an exceptional high tensile strength that enables manufacturers to develop lower-profile yet strong implants that support the trend towards and benefits of minimal invasive surgery. Dyneema Purity® TG also provides pliability, smoothness, a low coefficient of friction and fatigue and abrasion resistance. The product has been fully and successfully tested according to ISO standards for genotoxicity, cytotoxicity, sensitization/irritation, hemocompatibility, pyrogenicity and mutagenicity.

“Today’s minimally invasive procedures demand new instruments, technologies and materials, particularly thinner and smaller surgical devices and implants,” said Carina Snijder, business manager medical for DSM Dyneema.  “DSM is playing an important role in developing and improving advanced materials that allow medical device companies to develop more minimally invasive procedures. Building on our success with Dyneema Purity® in ultra-strong orthopedic implants, we are expanding our portfolio by targeting cardiovascular applications, among others. Through innovation, DSM aims to play a key role in developing better biomedical materials that allow medical device companies to develop devices that improve outcomes for patients.”